Skip to main content
. 2012 Oct 16;61(11):2906–2912. doi: 10.2337/db12-0145

FIG. 4.

FIG. 4.

MSC treatment accelerates wound closure and upregulates miR-146a level in diabetic wounds. A: Diabetic wounds at day (D) 7 treated with vehicle (left) and MSCs (right). B: Quantitative analysis of wound closure at day 7 in diabetic wounds treated with vehicle and MSCs (n = 10). C: CD45 immunostaining of sections from nondiabetic (C1, 3) and diabetic wounds (C2, 4) treated with vehicle (top) and MSCs (bottom). D: Fluorescent image demonstrates GFP signal at the wound edge (arrows indicate the injection sites). E: Real-time PCR analysis of miR-146a expression level in db/+ (Hz; n = 5) and db/db (n = 5) wounds at day 7 with MSC or vehicle treatment. *P < 0.05 comparing db/db wounds treated with MSCs with db/db wounds treated with vehicle. (A high-quality digital representation of this figure is available in the online issue.)